Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

STROME INVESTMENT MANAGEMENT LP

2. Date of Event Requiring Statement (Month/Day/Year)
07/21/2017

3. Issuer Name and Ticker or Trading Symbol
Zivo Bioscience, Inc. [OTCQB:ZIVO]

(Last)

(First)

(Middle)

100 WILSHIRE BLVD, SUITE 1750

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	__X__ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

SANTA MONICA, CA 90401

6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security
(Instr. 4)

2. Amount of Securities Beneficially Owned
(Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock Purchase Warrant	07/21/2017	07/20/2022	Common Stock	250,000	$ 0.1	I	See Footnote ⁽¹⁾ ⁽²⁾ ⁽³⁾
Common Stock Purchase Warrant	09/20/2017	09/19/2022	Common Stock	250,000	$ 0.1	I	See Footnote ⁽¹⁾ ⁽²⁾ ⁽³⁾
Common Stock Purchase Warrant	11/17/2017	11/16/2022	Common Stock	250,000	$ 0.1	I	See Footnote ⁽¹⁾ ⁽²⁾ ⁽³⁾
Convertible Debt	11/17/2017	09/30/2018	Common Stock	15,000,000	$ 0.1	I	See Footnote ⁽¹⁾ ⁽²⁾ ⁽³⁾
Common Stock Purchase Warrant	11/17/2017	11/16/2019	Common Stock	25,000,000	$ 0.1	I	See Footnote ⁽¹⁾ ⁽²⁾ ⁽³⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
STROME INVESTMENT MANAGEMENT LP 100 WILSHIRE BLVD, SUITE 1750 SANTA MONICA, CA 90401		X
STROME GROUP, INC. 100 WILSHIRE BLVD, SUITE 1750 SANTA MONICA, CA 90401		X
STROME MARK E 100 WILSHIRE BLVD, SUITE 1750 SANTA MONICA, CA 90401		X

Signatures

Kenneth R. Powell, Attorney-in-Fact by Power of Attorney		12/01/2017
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Two thirds of the common stock warrants and convertible debt, and the underlying shares of common stock, are held by Strome Mezzanine Fund, LP ("Strome Mezzanine") and one third are held by Strome Alpha Fund, L.P. ("Strome Alpha"). Strome Mezzanine and Strome Alpha received the common stock warrants and convertible debt pursuant to a Participation Agreement dated July 21, 2017 (the "Participation Agreement") with HEP Investments, LLC ("HEP") and Zivo Bioscience, Inc., as amended by the Amendment to Participation Agreement, Guaranty, Warrants and Amended and Restated Registration Rights Agreement dated November 15, 2017 (the "Amendment"). A copy of the Participation Agreement was filed with Strome Mezzanine's Schedule 13D on July 31, 2017, and a copy of the Amendment was filed with Strome Mezzanine's Schedule 13D/A on November 21, 2017.
(2)	Strome Investment Management, LP is the general partner of Strome Mezzanine and Strome Alpha. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark Strome is the President and CEO of Strome Group, Inc. Strome Investment Management, LP, Strome Group, Inc., and Mark Strome (the "Reporting Persons") may be deemed to share voting and investment power for the shares held by Strome Mezzanine and Strome Alpha.
(3)	Pursuant to Rule 16a-1(a)(4) of the Securities Exchange Act of 1934 ("Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.